HomeCYCC • NASDAQ
Cyclacel Pharmaceuticals Inc
$0.25
8.85%
-0.024 Today
After Hours:
$0.25
(3.79%)+0.0093
Closed: Apr 2, 5:36:09 PM UTC-4 · USD · NASDAQ · Disclaimer
Financials
Income Statement
-6M-4M-2M0
Revenue
Net Income
Revenue
Net income
(USD)Sep 2024Y/Y change
Revenue
10.00K-37.50%
Operating expense
2.19M-68.12%
Net income
-1.96M67.56%
Net profit margin
-19.57K48.09%
Earnings per share
-0.1897.55%
EBITDA
-2.18M68.18%
Effective tax rate
9.69%—
05M10M
Total Assets
Total Liabilities
Total assets
Total liabilities
(USD)Sep 2024Y/Y change
Cash and short-term investments
2.98M-49.83%
Total assets
5.38M-56.94%
Total liabilities
6.35M-22.55%
Total equity
-970.00K—
Shares outstanding
6.29M—
Price to book
-0.60—
Return on assets
-80.21%—
Return on capital
-32,014.71%—
-4M-2M02M
Net Change in Cash
Net change in cash
(USD)Sep 2024Y/Y change
Net income
-1.96M67.56%
Cash from operations
-3.07M24.01%
Cash from investing
——
Cash from financing
-1.00K98.00%
Net change in cash
-3.02M28.48%
Free cash flow
-2.31M8.20%
StockUS listed securityUS headquartered
Previous close
$0.27
Day range
$0.22 - $0.27
Year range
$0.22 - $4.00
Market cap
50.30M USD
Avg Volume
286.29K
P/E ratio
-
Dividend yield
-
Primary exchange
NASDAQ
About
Cyclacel Pharmaceuticals Inc. is a biotechnology firm based in Dundee, Scotland, and Short Hills, New Jersey, developing cancer drugs and treatments. Cyclacel was founded in 1996 by David Lane, Merlin Ventures and Cancer Research Campaign Technology with the University of Dundee and the University of Glasgow. Wikipedia
Founded
Aug 13, 1996
Employees
12
Discover more
You may be interested in
This list is generated from recent searches, followed securities, and other activity. Learn more

All data and information is provided “as is” for personal informational purposes only, and is not intended to be financial advice nor is it for trading purposes or investment, tax, legal, accounting or other advice. Google is not an investment adviser nor is it a financial adviser and expresses no view, recommendation or opinion with respect to any of the companies included in this list or any securities issued by those companies. Please consult your broker or financial representative to verify pricing before executing any trades. Learn more
People also search for
Search
Clear search
Close search
Main menu
Google apps